| Year |
Title |
Altmetric |
| 2023
|
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Clinical Pharmacology and Therapeutics.
113:615-623.
2023
|
|
| 2023
|
Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.
Clinical Pharmacology and Therapeutics.
113:585-599.
2023
|
|
| 2023
|
Does genetic testing offer utility as a supplement to traditional family health history intake for inherited disease risk?.
Family Practice.
2023
|
|
| 2023
|
Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis.
Clinical and Translational Science.
2023
|
|
| 2023
|
Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department.
Pediatric Emergency Care.
39:6-12.
2023
|
|
| 2023
|
Predictive models for abdominal aortic aneurysms using polygenic scores and PheWAS-derived risk factors.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
425-436.
2023
|
|
| 2023
|
Quantifying factors that affect polygenic risk score performance across diverse ancestries and age groups for body mass index.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
437-448.
2023
|
|
| 2022
|
Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations
2022
|
|
| 2022
|
Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients.
Frontiers in Pharmacology.
13.
2022
|
|
| 2022
|
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.
Clinical Pharmacology and Therapeutics.
112:959-967.
2022
|
|
| 2022
|
Arachidonate 5-lipoxygenase is essential for biosynthesis of specialized pro-resolving mediators and cardiac repair in heart failure
2022
|
|
| 2022
|
SMOC2 gene interacts with APOL1 in the development of end-stage kidney disease: A genome-wide association study.
Frontiers in Medicine.
9.
2022
|
|
| 2022
|
Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults.
Journal of the American Heart Association.
11.
2022
|
|
| 2022
|
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.
Genes.
13.
2022
|
|
| 2022
|
Genome-wide polygenic score to predict chronic kidney disease across ancestries.
Nature Medicine.
28:1412-1420.
2022
|
|
| 2022
|
APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.
American Journal of Nephrology.
53:182-190.
2022
|
|
| 2022
|
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
Clinical Pharmacology and Therapeutics.
111:950-955.
2022
|
|
| 2022
|
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association.
11.
2022
|
|
| 2022
|
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy.
Clinical and Translational Science.
15:371-383.
2022
|
|
| 2021
|
Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies.
Frontiers in Genetics.
12.
2021
|
|
| 2021
|
Genotype-Guided P2Y12 Inhibitor Therapy after Percutaneous Coronary Intervention: A Bayesian Analysis.
Journal of the American College of Cardiology.
14:731-739.
2021
|
|
| 2021
|
Evaluation of population-level pharmacogenetic actionability in Alabama.
Clinical and Translational Science.
14:2327-2338.
2021
|
|
| 2021
|
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.
Clinical Pharmacology and Therapeutics.
110:1368-1380.
2021
|
|
| 2021
|
Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.
Clinical Pharmacology and Therapeutics.
110:909-925.
2021
|
|
| 2021
|
Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
Clinical Pharmacology and Therapeutics.
110:179-188.
2021
|
|
| 2021
|
Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.
American Journal of Kidney Diseases.
78:151-153.
2021
|
|
| 2021
|
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
American Journal of Cardiology.
148:1-7.
2021
|
|
| 2021
|
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.
Clinical Pharmacology and Therapeutics.
109:1593-1605.
2021
|
|
| 2021
|
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical Pharmacology and Therapeutics.
109:705-715.
2021
|
|
| 2020
|
Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
JAMA Network Open.
3:e2029411.
2020
|
|
| 2020
|
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection (Genetics in Medicine, (2020), 22, 11, (1898-1902), 10.1038/s41436-020-0894-2).
Genetics in Medicine.
22:1919.
2020
|
|
| 2020
|
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in Medicine.
22:1898-1902.
2020
|
|
| 2020
|
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
2020
|
|
| 2020
|
Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction.
ESC Heart Failure.
7:1700-1710.
2020
|
|
| 2020
|
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Clinical Pharmacology and Therapeutics.
107:1420-1433.
2020
|
|
| 2020
|
Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.
Journal of Clinical Lipidology.
14:260-270.
2020
|
|
| 2020
|
Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples.
Clinical and Translational Science.
13:260-264.
2020
|
|
| 2020
|
Development of customizable implementation guides to support clinical adoption of pharmacogenomics: Experiences of the implementing genomics in practice (ignite) network.
Pharmacogenomics and Personalized Medicine.
13:217-226.
2020
|
|
| 2020
|
Improvement in kidney function after ventricular assist device implantation and its influence on thromboembolism, hemorrhage, and mortality.
ASAIO Journal.
268-276.
2020
|
|
| 2020
|
Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.
Hypertension.
75:246-256.
2020
|
|
| 2019
|
Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells.
Nature Communications.
10.
2019
|
|
| 2019
|
Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study.
Epilepsia.
60:2428-2436.
2019
|
|
| 2019
|
Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention.
Journal of the American Heart Association.
8.
2019
|
|
| 2019
|
Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.
American Journal of Hypertension.
32:1146-1153.
2019
|
|
| 2019
|
Racial differences in adult-onset MRI-negative temporal lobe epilepsy.
Epilepsy and Behavior.
100.
2019
|
|
| 2019
|
Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans.
Molecular Genetics and Genomic Medicine.
7.
2019
|
|
| 2019
|
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Genetics in Medicine.
21:2255-2263.
2019
|
|
| 2019
|
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.
Clinical Pharmacology and Therapeutics.
105:1477-1491.
2019
|
|
| 2019
|
Between a rock and a hard place: A high-risk patient with resistance to multiple P2Y12 antagonists.
Pharmacogenomics.
20:475-481.
2019
|
|
| 2019
|
Genome-wide meta-analysis of SNP-by9-ACEI/ARB and SNP-by-thiazide diuretic and effect on serum potassium in cohorts of European and African ancestry
2019
|
|
| 2019
|
A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study.
BMC Medical Genomics.
12.
2019
|
|
| 2019
|
CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Pediatric Transplantation.
23.
2019
|
|
| 2018
|
Pharmacogenetics of warfarin dosing in patients of African and European ancestry.
Pharmacogenomics.
19:1357-1371.
2018
|
|
| 2018
|
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical Pharmacology and Therapeutics.
104:664-674.
2018
|
|
| 2018
|
Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage
2018
|
|
| 2018
|
Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction.
Journal of Molecular and Cellular Cardiology.
118:70-80.
2018
|
|
| 2018
|
Racial disparities in temporal lobe epilepsy.
Journal of epilepsy.
140:56-60.
2018
|
|
| 2018
|
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC: Cardiovascular Interventions.
11:181-191.
2018
|
|
| 2017
|
Genome-wide admixture and association study of subclinical atherosclerosis in the Women’s Interagency HIV Study (WIHS).
PLoS One.
12.
2017
|
|
| 2017
|
Clinical and genetic predictors of delayed remission after multiple levels of antidepressant treatment: Toward early identification of depressed individuals for advanced care options.
Journal of Clinical Psychiatry.
78:e1291-e1298.
2017
|
|
| 2017
|
Comparison of two point-of-care cyp2c19 genotyping assays for genotype-guided antiplatelet therapy.
Annals of Clinical and Laboratory Science.
47:738-743.
2017
|
|
| 2017
|
Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage
2017
|
|
| 2017
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Clinical Pharmacology and Therapeutics.
102:397-404.
2017
|
|
| 2017
|
Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.
Clinical Pharmacology and Therapeutics.
102:493-501.
2017
|
|
| 2017
|
Implementation and utilization of the molecular tumor board to guide precision medicine..
Oncotarget.
8:57845-57854.
2017
|
|
| 2017
|
Age and sex disparities in discharge statin prescribing in the stroke belt: Evidence from the reasons for geographic and racial differences in stroke study.
Journal of the American Heart Association.
6.
2017
|
|
| 2017
|
Differential Impact of Risk Factors in Blacks and Whites in the Development of Atrial Fibrillation: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study.
Journal of Racial and Ethnic Health Disparities.
4:718-724.
2017
|
|
| 2017
|
Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
Pharmacogenomics.
18:1059-1073.
2017
|
|
| 2017
|
Racial differences in statin adherence following hospital discharge for ischemic stroke.
Neurology.
88:1839-1848.
2017
|
|
| 2017
|
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Clinical and Translational Science.
10:143-146.
2017
|
|
| 2017
|
Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events among African Americans in 2 Large Cohort Studies.
Circulation: Cardiovascular Genetics.
10.
2017
|
|
| 2017
|
Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation.
International Journal of Cardiology.
227:808-812.
2017
|
|
| 2017
|
Anticoagulation control in patients with ventricular assist devices.
ASAIO Journal.
63:759-765.
2017
|
|
| 2017
|
Implementation and utilization of the molecular tumor board to guide precision medicine.
Oncotarget.
8:57845-57854.
2017
|
|
| 2017
|
Local ancestry and clinical cardiovascular events among African Americans from the atherosclerosis risk in communities study.
Journal of the American Heart Association.
6.
2017
|
|
| 2017
|
Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.
Pharmacogenetics and Genomics.
27:347-355.
2017
|
|
| 2017
|
Whole exome analyses to examine the impact of rare variants on left ventricular traits in African American participants from the HyperGEN and GENOA studies.
2017
|
|
| 2016
|
High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study).
American Journal of Cardiology.
118:1826-1830.
2016
|
|
| 2016
|
Addressing stroke risk factors in Black and White Americans: Findings from the national health and nutrition examination survey, 2009-2010
2016
|
|
| 2016
|
US mortality: Influence of race, geography and cardiovascular risk among participants in the population-based REGARDS cohort.
Journal of Racial and Ethnic Health Disparities.
3:599-607.
2016
|
|
| 2016
|
A systematic analysis and comparison of warfarin initiation strategies.
Pharmacogenetics and Genomics.
26:445-452.
2016
|
|
| 2016
|
Comparison of approaches for stroke prophylaxis in patients with non-valvular atrial fibrillation: Network meta-analyses of randomized controlled trials.
PLoS One.
11.
2016
|
|
| 2016
|
Pharmacogenetics in Cardiovascular Medicine..
Current Genetic Medicine Reports.
4:119-129.
2016
|
|
| 2016
|
Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.
American Journal of Cardiology.
118:232-236.
2016
|
|
| 2016
|
Valvular Heart disease and acquired type 2A von willebrand syndrome: The "hemostatic" waring blender syndrome.
JAMA Cardiology.
1:205-206.
2016
|
|
| 2016
|
APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
Nephrology Dialysis Transplantation.
31:602-608.
2016
|
|
| 2016
|
Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage among Warfarin Users
2016
|
|
| 2016
|
Paroxysmal atrial fibrillation and the hazards of under-treatment.
International Journal of Cardiology.
202:214-220.
2016
|
|
| 2015
|
Predictors of thromboembolic events in patients with ventricular assist device.
ASAIO Journal.
61:640-647.
2015
|
|
| 2015
|
Race influences warfarin dose changes associated with genetic factors.
Blood.
126:539-545.
2015
|
|
| 2015
|
Genome-wide association study of warfarin maintenance dose in a Brazilian sample.
Pharmacogenomics.
16:1253-1263.
2015
|
|
| 2015
|
Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study.
American Journal of Kidney Diseases.
65:701-709.
2015
|
|
| 2015
|
Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.
Circulation: Cardiovascular Quality and Outcomes.
8:8-14.
2015
|
|
| 2014
|
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.
Blood.
124:2298-2305.
2014
|
|
| 2014
|
Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications
2014
|
|
| 2014
|
RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS).
Atherosclerosis.
233:666-672.
2014
|
|
| 2014
|
The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study..
Frontiers in Pharmacology.
5:210.
2014
|
|
| 2013
|
Vitamin K intake, body mass index and warfarin maintenance dose
2013
|
|
| 2013
|
Influence of kidney function on risk of hemorrhage among patients taking warfarin: A cohort study.
American Journal of Kidney Diseases.
61:354-357.
2013
|
|
| 2013
|
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
New England Journal of Medicine.
369:2283-2293.
2013
|
|
| 2013
|
Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study
2013
|
|
| 2013
|
Pathway analysis of genome-wide data improves warfarin dose prediction..
BMC Genomics.
14 Suppl 3.
2013
|
|
| 2013
|
Reversal of oral anticoagulation
2013
|
|
| 2012
|
Warfarin pharmacogenetics: Challenges and opportunities for clinical translation.
Frontiers in Pharmacology.
3 OCT.
2012
|
|
| 2012
|
Use of secondary prevention medications among adults with reduced kidney function.
Clinical Journal of the American Society of Nephrology.
7:604-611.
2012
|
|
| 2012
|
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Thrombosis and Haemostasis.
107:232-240.
2012
|
|
| 2012
|
Prevalence and Correlates of Low Medication Adherence in Apparent Treatment-Resistant Hypertension.
Journal of the CardioMetabolic Syndrome.
14:694-700.
2012
|
|
| 2011
|
High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.
Bioinformatics.
27:1384-1389.
2011
|
|
| 2011
|
Preference-based quality-of-life measures for neocortical epilepsy surgery.
Epilepsia.
52:1018-1020.
2011
|
|
| 2011
|
Controlling population structure in human genetic association studies with samples of unrelated individuals.
Statistics and its Interface.
4:317-326.
2011
|
|
| 2011
|
Practical consideration of genotype imputation: Sample size, window size, reference choice, and untyped rate.
Statistics and its Interface.
4:339-352.
2011
|
|
| 2010
|
Warfarin dosing in patients with impaired kidney function.
American Journal of Kidney Diseases.
56:823-831.
2010
|
|
| 2010
|
Expectations, validity, and reality in pharmacogenetics.
Journal of Clinical Epidemiology.
63:960-969.
2010
|
|
| 2010
|
Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Blood.
115:3827-3834.
2010
|
|
| 2010
|
Integration of genetic, clinical, and INR data to refine warfarin dosing.
Clinical Pharmacology and Therapeutics.
87:572-578.
2010
|
|
| 2009
|
Hyperammonemia following intravenous valproate loading.
Journal of epilepsy.
85:65-71.
2009
|
|
| 2009
|
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Blood Cells, Molecules and Diseases.
43:119-128.
2009
|
|
| 2009
|
Effect of epilepsy magnetic source imaging on intracranial electrode placement.
Annals of Neurology.
65:716-723.
2009
|
|
| 2009
|
Warfarin pharmacogenomics.
Current Opinion in Molecular Therapeutics.
11:243-251.
2009
|
|
| 2009
|
Kidney function influences warfarin responsiveness and hemorrhagic Complications.
Journal of the American Society of Nephrology.
20:912-921.
2009
|
|
| 2009
|
A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.
Blood Cells, Molecules and Diseases.
42:155-158.
2009
|
|
| 2009
|
Estimation of the warfarin dose with clinical and pharmacogenetic data..
New England Journal of Medicine.
360:753-764.
2009
|
|
| 2008
|
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.
Pharmacogenomics.
9:1331-1346.
2008
|
|
| 2008
|
VKORC1 polymorphims, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics.
9:1445-1458.
2008
|
|
| 2008
|
Warfarin pharmacogenetics
2008
|
|
| 2008
|
Functional imaging: I. Relative predictive value of intracranial electroencephalography.
Annals of Neurology.
64:25-34.
2008
|
|
| 2008
|
Functional imaging: II. Prediction of epilepsy surgery outcome.
Annals of Neurology.
64:35-41.
2008
|
|
| 2008
|
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Pharmacogenomics.
9:511-526.
2008
|
|
| 2008
|
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
Clinical Pharmacology and Therapeutics.
83:312-321.
2008
|
|
| 2007
|
Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.
Journal of Clinical Pharmacy and Therapeutics.
32:365-371.
2007
|
|
| 2007
|
Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans.
Personalized Medicine.
4:157-169.
2007
|
|
| 2007
|
Safety of rapid intravenous loading of valproate.
Epilepsia.
48:478-483.
2007
|
|
| 2006
|
Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.
Blood Cells, Molecules and Diseases.
37:100-106.
2006
|
|
| 2006
|
Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: An update.
Obesity Reviews.
7:79-88.
2006
|
|
| 2005
|
Efficacy of rapid IV administration of valproic acid for status epilepticus [3] (multiple letters).
Neurology.
65:500-501.
2005
|
|
| 2005
|
Efficacy of rapid IV administration of valproic acid for status epilepticus.
Neurology.
64:353-355.
2005
|
|
| 2004
|
Superiority of fixed-dose warfarin for chronic anticoagulation.
Journal of Stroke and Cerebrovascular Diseases.
13:118-121.
2004
|
|
| 2003
|
Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.
Neurology.
60:1991-1992.
2003
|
|
| 2001
|
Rasmussen's Encephalitis..
Current Treatment Options in Neurology.
3:555-563.
2001
|
|
| 2000
|
The safety of rapid valproic acid infusion.
Epilepsia.
41:1342-1345.
2000
|
|
